Immuneering (IMRX) EBIT (2020 - 2026)

Immuneering's EBIT history runs 7 years deep, the most recent figure standing at -$15.3 million for Q1 2026.

• In Q1 2026, EBIT rose 0.97% year-over-year to -$15.3 million; the TTM figure through Mar 2026 stood at -$59.2 million (up 7.79% YoY), while the FY2025 annual figure was -$59.4 million, up 7.33% from the prior year.
• EBIT for Q1 2026 stood at -$15.3 million, down from -$13.8 million in the prior quarter.
• The five-year high for EBIT was -$11.6 million in Q2 2022, with the low at -$18.6 million in Q4 2024.
• The 5-year median for EBIT is -$14.8 million (2025), against an average of -$14.6 million.
• The sharpest annual moves came in 2022 and 2025: EBIT plunged 107.27% in 2022, then climbed 25.89% in 2025.
• Immuneering's EBIT stood at -$14.0 million in 2022, then dropped by 16.57% to -$16.3 million in 2023, then dropped by 13.84% to -$18.6 million in 2024, then grew by 25.89% to -$13.8 million in 2025, then dropped by 11.51% to -$15.3 million in 2026.
• Business Quant data shows IMRX's EBIT at -$15.3 million in Q1 2026, -$13.8 million in Q4 2025, and -$15.4 million in Q3 2025.